Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
B-Fine: intrahepatic immunophenotyping of bepirovirsen in chronic hepatitis B
2020-002000-39Phase 2Completed
- Sponsor
- GSK
- Start
- Jul 2020
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bepirovirsen in Chronic Hepatitis B (CHB), sponsored by GSK. Primary endpoint: Serum HBsAg change after 12 weeks of GSK3228836. Started Jul 2020; status: completed.
02
Drugs
bepirovirsen
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on 2020-002000-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-002000-39.